₹30.40
(Market cap
₹1,473 Cr
Recently Viewed
Clear AllMarket cap
₹1,473 Cr
Revenue (TTM)
₹447 Cr
P/E Ratio
42
P/B Ratio
4.7
Div. Yield
0.1 %
Value Research Rating
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹35 Cr
ROE
7.8 %
ROCE
9.4 %
Industry P/E
50.32
EV/EBITDA
22.6
Debt to Equity
0.3
Book Value
₹511.3
EPS
₹56.8
Face value
5
Shares outstanding
6,178,024
CFO
₹202.78 Cr
EBITDA
₹392.84 Cr
Net Profit
₹256.93 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NGL Fine-Chem
| 68.0 | -1.8 | 61.5 | 120.5 | 20.1 | -- | -- |
|
BSE Healthcare
| -2.4 | -2.6 | -3.9 | 5.9 | 24.1 | 13.8 | 10.8 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
NGL Fine-Chem
| -22.0 | -16.2 | 45.2 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NGL Fine-Chem
|
2,361.8 | 1,472.8 | 446.9 | 35.1 | 8.7 | 12 | 42 | 4.7 |
| 2,751.0 | 34,358.6 | 5,201.6 | 1,014.6 | 22.9 | 25 | 33.9 | 7.5 | |
| 8,051.0 | 20,145.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 100.3 | 24.2 | |
| 1,604.9 | 30,442.4 | 8,850.1 | 894.8 | 15.2 | 19.8 | 35 | 6.1 | |
| 1,428.5 | 1,212.3 | 314.4 | 36.7 | 17.3 | 12.6 | 29.6 | 3.5 | |
| 1,970.2 | 31,628.5 | 4,193.0 | 753.8 | 22.7 | 20.8 | 42 | 7.9 | |
| 4,749.1 | 21,777.1 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.5 | 5.5 | |
| 143.0 | 19,001.6 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 205.0 | 8,966.7 | 2,125.5 | 96.1 | 10.6 | 13.3 | 116.7 | 10.0 | |
| 1,369.7 | 22,204.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1009.3 | 4.8 |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical... ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, rafoxanide, diminazene aceturate, s-methoprene, carprofen, diminazene diaceturate, ractopamine HCI, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, fenbendazole, and xylazine hydrochloride. It also provides human health pharmaceutical ingredients, including nitazoxanide and atovaquone; and intermediates and specialty chemicals comprising 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-ethyl glucamine. In addition, the company offers finished dosage forms, including diminazene aceturate granules and homidium chloride tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India. Read more
Incorporated
1981
Chairman
Dhananjay Mungale
Managing Director
Rahul Nachane
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of NGL Fine-Chem Ltd is ₹2,361.80 (NSE) and ₹2,371.15 (BSE) as of 09-Apr-2026 IST. NGL Fine-Chem Ltd has given a return of 20.1% in the last 3 years.
The P/E ratio of NGL Fine-Chem Ltd is 41.96 times as on 09-Apr-2026, a 17 discount to its peers’ median range of 50.32 times.
The P/B ratio of NGL Fine-Chem Ltd is 4.66 times as on 09-Apr-2026, a 37 discount to its peers’ median range of 7.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
32.97
|
2.44
|
|
2024
|
31.37
|
4.92
|
|
2023
|
36.22
|
3.32
|
|
2022
|
24.27
|
5.95
|
|
2021
|
16.74
|
6.13
|
The 52-week high and low of NGL Fine-Chem Ltd are Rs 2,575.00 and Rs 980.00 as of 09-Apr-2026.
NGL Fine-Chem Ltd has a market capitalisation of ₹ 1,473 Cr as on 09-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in NGL Fine-Chem Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.